Dr Reddy’s Q1FY27 profit falls 69% as US sales and semaglutide supply weaken
Dr Reddy’s reported Q1FY27 net profit of ₹443 crore, down 69% year-on-year, with revenue falling 5.6% to ₹8,071 crore. US revenue dropped 35%, while India, Europe and emerging markets posted double-digit growth. The company expects semaglutide supply to potentially resume around November.
What happened
Dr. Reddy’s Laboratories · Dr Reddy’s Q1FY27 profit fell 69% as US sales and generic semaglutide supply were hit. India, Europe and emerging markets grew in
Key facts
- Q1FY27 net profit: ₹443 crore, down 69% year-on-year
- Revenue: ₹8,071 crore, down 5.6% year-on-year
- EBITDA: ₹1,009 crore, down 56% year-on-year
- US revenue: ₹2,205 crore, down 35% year-on-year
- Net cash surplus: ₹3,058 crore
- Expected semaglutide sales: 6-7 million units this fiscal
Why this matters
The US dependence exposed by the semaglutide disruption strengthens the case for partnerships, licensing or capacity investments that diversify complex-generic supply and deepen faster-growing international markets.
What to watch
- Confirmation of semaglutide supply resumption, including timing, approved volumes and market availability.
- Quarterly US revenue trend and management commentary on customer inventory, pricing and new launches.
- Gross-margin and EBITDA-margin movement as lower US mix affects profitability.
- Sustained double-digit growth rates in India, Europe and emerging markets.
- Any FDA, manufacturing-site, import-alert or supply-chain developments affecting US product availability.
- Competitor semaglutide launches, pricing actions and market-share changes.
- Prioritize regulatory, manufacturing and channel-readiness actions needed to resume semaglutide supply around November.
- Use India, Europe and emerging-market momentum to protect revenue growth through launches, field-force investment and distribution expansion.
- Tighten discretionary spending and optimize product mix to defend margins during the US revenue trough.
- Provide clearer guidance on the timing, scale and economics of semaglutide resupply to reduce investor uncertainty.
- Accelerate alternative US launches and complex-generic opportunities to reduce dependence on a single disrupted product.